Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: A New CEO at Quanterix; VP at Biodesix; and More


Quanterix announced this week it has appointed Paul Chapman as its new president and CEO, replacing Martin Madaus, who will continue at the company as executive chairman.

Chapman was previously vice president of EMD Millipore's BioPharm Processing Solutions business. Before that he was vice president of hospital solutions for Roche Near Patient Testing in Austria.

Biodesix this week appointed Dominic Spinella vice president of clinical development and medical affairs.

Spinella was previously executive director and head of translational and molecular medicine for Pfizer's biotherapeutics division. Prior to that he was head of translational medicine for Pfizer Oncology as well as vice president of exploratory research at Chugai Pharmaceuticals.

Opko Health has appointed Juan Rodriguez as senior vice president and chief financial officer.

Rodriguez was previously a consultant to software firm Cognitec Systems. Before that he held a number of executive positions at Kos Pharmaceuticals, which was acquired in 2007 by Abbott Laboratories.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.